The future of gold: the full hedge role is at risk

Historically, correlation among different risky assets has increased during periods of financial crisis: losses in one market spread to others, thus creating “contagion”. The increased correlation phenomenon is confirmed by our previous analysis on the topic (https://bsic.it/new-old-high-correlation/). Furthermore, there is also the so-called “flight to quality”, meaning that investors move Read more…

Starwood – Marriott: Star Marriage or a Walkaway?

Starwood Hotels & Resorts Worldwide Inc.; Market Cap: $12.18bn (as of 19/11/2015) Marriott International Inc.; Market Cap: $ 18.64bn (as of 19/11/2015)   Introduction On November 16, Marriott International, Inc. (NASDAQ:MAR) and Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT) announced that the boards of directors of both companies unanimously Read more…

Ferrari: too fast outside the circuit?

[edmc id= 3236]Download here the Ferrari Pitch[/edmc] After having covered the IPO of Ferrari (https://bsic.it/wanna-flawless-ferrari-52-now-feasible/) in detail a couple of weeks ago, we are now trying to identify RACE’s market positioning in terms of multiples. The structure of the analysis is as follows: firstly, we plot Ferrari’s positioning against major automakers Read more…

Want a robust quality drug pipeline? – Pay super premium!: Alexion to acquire Synageva in an $8.4bn deal

Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn   Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…